[go: up one dir, main page]

WO2002020754A3 - Molecules utilisees a des fins diagnostiques et therapeutiques - Google Patents

Molecules utilisees a des fins diagnostiques et therapeutiques Download PDF

Info

Publication number
WO2002020754A3
WO2002020754A3 PCT/US2001/027127 US0127127W WO0220754A3 WO 2002020754 A3 WO2002020754 A3 WO 2002020754A3 US 0127127 W US0127127 W US 0127127W WO 0220754 A3 WO0220754 A3 WO 0220754A3
Authority
WO
WIPO (PCT)
Prior art keywords
dithp
provides
therapeutics
diagnostics
diagnostic assays
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/027127
Other languages
English (en)
Other versions
WO2002020754A2 (fr
Inventor
Jackson Stuart
Stephen E Lincoln
Christina M Altus
Gerard E Dufour
Michael S Chalup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Priority to CA002421265A priority Critical patent/CA2421265A1/fr
Priority to EP01966454A priority patent/EP1364015A2/fr
Priority to AU8696401A priority patent/AU8696401A/xx
Publication of WO2002020754A2 publication Critical patent/WO2002020754A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002020754A3 publication Critical patent/WO2002020754A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des polynucléotides humains purifiés utilisés à des fins diagnostiques et thérapeutiques (dithp). Elle concerne également les polypeptides (DITHP) codés par ces dithp, ainsi qu'à l'utilisation de ces dithp, ou de leurs compléments, oligonucléotides ou fragments dans des analyses diagnostiques. L'invention concerne en outre des vecteurs et cellules hôtes contenant ces dithp et permettant l'expression de DITHP, ainsi que l'utilisation de tels DITHP isolés et purifiés pour induire des anticorps et pour analyser des banques de composés, et l'utilisation des anticorps anti-DITHP dans des analyses diagnostiques. L'invention concerne enfin des micro-ensembles contenant des dithp et leur procédés d'utilisation.
PCT/US2001/027127 2000-09-05 2001-08-29 Molecules utilisees a des fins diagnostiques et therapeutiques Ceased WO2002020754A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002421265A CA2421265A1 (fr) 2000-09-05 2001-08-29 Molecules utilisees a des fins diagnostiques et therapeutiques
EP01966454A EP1364015A2 (fr) 2000-09-05 2001-08-29 Molecules pour diagnostic et traitement
AU8696401A AU8696401A (en) 2000-09-05 2001-09-02 Molecules for diagnostics and therapeutics

Applications Claiming Priority (44)

Application Number Priority Date Filing Date Title
US22974800P 2000-09-05 2000-09-05
US22974700P 2000-09-05 2000-09-05
US22975100P 2000-09-05 2000-09-05
US22975000P 2000-09-05 2000-09-05
US23058300P 2000-09-05 2000-09-05
US22974900P 2000-09-05 2000-09-05
US60/229,747 2000-09-05
US60/229,748 2000-09-05
US60/229,749 2000-09-05
US60/229,751 2000-09-05
US60/230,583 2000-09-05
US60/229,750 2000-09-05
US23051400P 2000-09-06 2000-09-06
US23051900P 2000-09-06 2000-09-06
US23098800P 2000-09-06 2000-09-06
US23051700P 2000-09-06 2000-09-06
US23051800P 2000-09-06 2000-09-06
US23061000P 2000-09-06 2000-09-06
US23059500P 2000-09-06 2000-09-06
US23050500P 2000-09-06 2000-09-06
US23059900P 2000-09-06 2000-09-06
US23051500P 2000-09-06 2000-09-06
US23086500P 2000-09-06 2000-09-06
US23059800P 2000-09-06 2000-09-06
US23059700P 2000-09-06 2000-09-06
US60/230,988 2000-09-06
US60/230,595 2000-09-06
US60/230,519 2000-09-06
US60/230,597 2000-09-06
US60/230,515 2000-09-06
US60/230,865 2000-09-06
US60/230,505 2000-09-06
US60/230,598 2000-09-06
US60/230,518 2000-09-06
US60/230,599 2000-09-06
US60/230,517 2000-09-06
US60/230,610 2000-09-06
US60/230,514 2000-09-06
US23116300P 2000-09-07 2000-09-07
US23095100P 2000-09-07 2000-09-07
US23116700P 2000-09-07 2000-09-07
US60/230,951 2000-09-07
US60/231,163 2000-09-07
US60/231,167 2000-09-07

Publications (2)

Publication Number Publication Date
WO2002020754A2 WO2002020754A2 (fr) 2002-03-14
WO2002020754A3 true WO2002020754A3 (fr) 2003-09-25

Family

ID=27586647

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027127 Ceased WO2002020754A2 (fr) 2000-09-05 2001-08-29 Molecules utilisees a des fins diagnostiques et therapeutiques

Country Status (3)

Country Link
EP (1) EP1364015A2 (fr)
CA (1) CA2421265A1 (fr)
WO (1) WO2002020754A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102637A1 (en) * 2000-12-21 2002-08-01 Chunhua Yan Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002074906A2 (fr) * 2001-03-16 2002-09-26 Eli Lilly And Company Proteines de mammiferes lp et reactifs associes
US8163892B2 (en) 2002-07-08 2012-04-24 Oncolys Biopharma, Inc. Oncolytic virus replicating selectively in tumor cells
WO2005019258A2 (fr) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045712A2 (fr) * 1997-04-08 1998-10-15 Human Genome Sciences, Inc. 20 proteines humaines secretees
WO1998048274A1 (fr) * 1997-04-22 1998-10-29 Smithkline Beecham Corporation Test par fluorescence homogene pour mesurer l'effet des composes sur l'expression d'un gene
WO1999025825A2 (fr) * 1997-11-13 1999-05-27 Genset ADNc ETENDUS POUR PROTEINES SECRETEES
WO2001055301A2 (fr) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
WO2001090325A2 (fr) * 2000-05-19 2001-11-29 Millennium Pharmaceuticals, Inc. 50365, un nouveau membre de la famille hexokinase et utilisations
WO2002008399A2 (fr) * 2000-07-21 2002-01-31 Incyte Genomics, Inc. Kinases humaines

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045712A2 (fr) * 1997-04-08 1998-10-15 Human Genome Sciences, Inc. 20 proteines humaines secretees
WO1998048274A1 (fr) * 1997-04-22 1998-10-29 Smithkline Beecham Corporation Test par fluorescence homogene pour mesurer l'effet des composes sur l'expression d'un gene
WO1999025825A2 (fr) * 1997-11-13 1999-05-27 Genset ADNc ETENDUS POUR PROTEINES SECRETEES
WO2001055301A2 (fr) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
WO2001090325A2 (fr) * 2000-05-19 2001-11-29 Millennium Pharmaceuticals, Inc. 50365, un nouveau membre de la famille hexokinase et utilisations
WO2002008399A2 (fr) * 2000-07-21 2002-01-31 Incyte Genomics, Inc. Kinases humaines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] EBI Hinxton, UK; 30 November 1999 (1999-11-30), NCI.CGAP: "National Cancer Institute, Cancer Genome Anatomy Project (CGAP)", XP002218725, Database accession no. AW194769 *
NISHI S ET AL: "HUMAN HEXOKINASE SEQUENCES OF AMINO AND CARBOXYL-TERMINAL HALVES ARE HOMOLOGOUS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 157, no. 3, 1988, pages 937 - 943, XP002218724, ISSN: 0006-291X *

Also Published As

Publication number Publication date
CA2421265A1 (fr) 2002-03-14
WO2002020754A2 (fr) 2002-03-14
EP1364015A2 (fr) 2003-11-26

Similar Documents

Publication Publication Date Title
WO2002097031A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2004023973A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2000073509A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2002083876A3 (fr) Molecules secretoires
PL399351A1 (pl) Czasteczka przeciwciala, zwiazek ja zawierajacy, sekwencja DNA, wektor do klonowania lub ekspresji, komórka gospodarza, sposób wytwarzania czasteczki przeciwciala, kompozycja terapeutyczna lub diagnostyczna, zastosowanie czasteczki lub zwiazku
WO2004037999A3 (fr) Adn et proteines 3 de type a34 et a33, anticorps associes et methodes de traitement associees
HUP0401591A2 (hu) Új receptor-nukleinsavak és- polipeptidek
WO2001004264A3 (fr) Genes associes a l'atherosclerose
WO2002046228A3 (fr) Recepteur de la toxine du b. anthracis
WO2001068859A3 (fr) Molecules du type recepteur de l'interleukine 17 et leur utilisation
WO2001068705A3 (fr) Molecules du type recepteur de l'interleukine 17 et leurs utilisations
WO2003062376A3 (fr) Molécules pour le diagnostic et la thérapeutique
WO2002020756A3 (fr) Molécules sécrétoires
WO2002040715A8 (fr) Molecules permettant la detection et le traitement de maladies
WO2001062927A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2001062922A3 (fr) Molecules destinees a la detection et au traitement de maladies
WO2002020754A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2003062385A3 (fr) Molecules secretoires
WO2001062918A3 (fr) Molecules secretoires
WO2002055738A3 (fr) Molecules pour la detection et le traitement de maladies
WO2002079473A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2001021836A3 (fr) Molecules pour le diagnostic et la therapeutique
WO2002018576A3 (fr) Compositions et methodes associees aux genes specifiques du poumon
WO2001061055A3 (fr) Procedes de diagnostic, de monitorage, de stadage, d'imagerie et de traitement du cancer du poumon par le biais de genes specifiques du cancer du poumon
WO2000075298A3 (fr) Molecules pour la detection et le traitement de maladies

Legal Events

Date Code Title Description
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2421265

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001966454

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001966454

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001966454

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP